Cargando…
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
BACKGROUND: Somatic mutations in the gene for the epidermal growth factor receptor (EGFR) are found in adenocarcinomas of the lung and are associated with sensitivity to the kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Lung adenocarcinomas also harbor activating mutations in the dow...
Autores principales: | Pao, William, Wang, Theresa Y, Riely, Gregory J, Miller, Vincent A, Pan, Qiulu, Ladanyi, Marc, Zakowski, Maureen F, Heelan, Robert T, Kris, Mark G, Varmus, Harold E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545207/ https://www.ncbi.nlm.nih.gov/pubmed/15696205 http://dx.doi.org/10.1371/journal.pmed.0020017 |
Ejemplares similares
-
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005) -
KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma
por: Rekhtman, Natasha, et al.
Publicado: (2013) -
Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005) -
Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011) -
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers
por: Drilon, Alexander, et al.
Publicado: (2019)